CR11563A - SOLID PHARMACEUTICAL DOSE FORM - Google Patents

SOLID PHARMACEUTICAL DOSE FORM

Info

Publication number
CR11563A
CR11563A CR11563A CR11563A CR11563A CR 11563 A CR11563 A CR 11563A CR 11563 A CR11563 A CR 11563A CR 11563 A CR11563 A CR 11563A CR 11563 A CR11563 A CR 11563A
Authority
CR
Costa Rica
Prior art keywords
dose form
solid pharmaceutical
pharmaceutical dose
amodiaquine
artesunate
Prior art date
Application number
CR11563A
Other languages
Spanish (es)
Inventor
Lulla Amar
Malhotra Geena
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of CR11563A publication Critical patent/CR11563A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica la cual comprende una forma solida de dosis unitaria la cual comprende: uno o mas de los ingredientes activos farmacéuticamente seleccionados de valaciclovir, olanzapina, voriconazol, topotecan, artesunato, amodiaquina.A pharmaceutical composition is described which comprises a solid unit dose form which comprises: one or more of the pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine.

CR11563A 2008-01-11 2010-07-09 SOLID PHARMACEUTICAL DOSE FORM CR11563A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN89MU2008 2008-01-11
IN619MU2008 2008-03-24

Publications (1)

Publication Number Publication Date
CR11563A true CR11563A (en) 2011-01-12

Family

ID=51359609

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11563A CR11563A (en) 2008-01-11 2010-07-09 SOLID PHARMACEUTICAL DOSE FORM

Country Status (1)

Country Link
CR (1) CR11563A (en)

Similar Documents

Publication Publication Date Title
PH12016500756A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
EA201200937A1 (en) SOLID MEDICINE FORM TICAGRELOR
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
SV2011004061A (en) ARIL-PIRIDINAS AS INHIBITORS OF SINTASA DE ALDOSTERONA
UY33075A (en) CYCLHEXAN DERIVATIVES AND USES OF THE SAME
ECSP099775A (en) COMBINATION THERAPY WITH A COMPOUND ACTING AS AN ADP PLAQUETARY RECEIVER INHIBITOR
WO2009088414A3 (en) Oral pharmaceutical dosage forms
JO3425B1 (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
NI200900040A (en) 5-SUBSTITUTE QUINAZOLINONE DERIVATIVES AS ANTITUMORAL AGENTS.
MX2016006336A (en) Pyrazolopyrimidine compounds.
EA201691058A1 (en) DERIVATIVES OF PYRROLOPIRROLON AND THEIR APPLICATION FOR THE TREATMENT OF DISEASES
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
CU20160192A7 (en) INDANO AND INDOLINA DERIVATIVES USEFUL AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.
EA201101118A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING 2-OXO-1-PYRROLIDINE DERIVATIVES
MX2017012295A (en) Formylated n-heterocyclic derivatives as fgfr4 inhibitors.
EA201300034A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM
MX2016014939A (en) CARBOXAMIDE DERIVATIVES
UY35209A (en) TRICYCLIC COMPOUNDS
EA201290229A1 (en) SPIROLACTAM DERIVATIVES AND THEIR APPLICATION
EA201391524A1 (en) GLYCOSIDE DERIVATIVES AND THEIR APPLICATION
UY33348A (en) FUROPIRIDINE COMPOUNDS AND USES OF THE SAME
JO3192B1 (en) Benzothiazolone compound
CR11563A (en) SOLID PHARMACEUTICAL DOSE FORM